Home Featured Page 142

Featured

Latest

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK...

From Dendrites to Drug Discovery: An Interview with Dr. Alex Kwan

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for...

Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial...

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data...

1...141142143...301 Page 142 of 301

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK...

From Dendrites to Drug Discovery: An Interview with Dr. Alex Kwan

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for...

Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial...

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data...

EDITOR PICKS

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY